NEW YORK, July 23, 2014 /PRNewswire/ --
Today, Analysts Review released its research reports regarding Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK), AstraZeneca plc (NYSE: AZN), Novartis AG (NYSE: NVS) and Teva Pharmaceutical Industries Ltd. (NYSE: TEVA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5022-100free.
--
Johnson & Johnson Research Reports
On July 15, 2014, Johnson & Johnson reported Q2 2014 financial results. In Q2 2014, the Company generated sales of $19.5 billion, up 9.1% YoY. Q2 2014 net earnings were $4.3 billion, or $1.51 per diluted share, compared with $3.8 billion, or $1.33 per diluted share, in Q2 2013. "Our strong second-quarter results reflect the continued success of our new product launches and the progress we have made in achieving our near-term priorities," said Alex Gorsky, Chairman CEO of Johnson & Johnson. "Significant advancements are being made in the treatment options and access to care for patients and customers around the world. Our diversified business model, focus on long-term growth drivers and talented colleagues position us well in this evolving and dynamic global health care market." For full year 2014, the Company increased its earnings guidance to $5.85 to $5.92 per share. The full research reports on Johnson & Johnson are available to download free of charge at:
http://www.analystsreview.com/Jul-23-2014/JNJ/report.pdf
--
Merck & Co., Inc. Research Reports
On July 17, 2014, Merck & Co., Inc. (Merck) announced that music industry promoter and HIV advocate Maria Davis and Positive Women's Network-USA (PWN-USA) are joining the Company's national HIV education campaign, "I Design." The said program aims to help inspire and motivate women living with HIV to express their sentiments on their treatment plans, as well as to work their healthcare teams to design treatment plans specific to the patients' individual health needs. "As an organization founded to build collective power among women living with HIV, we are glad to partner with Merck and the I Design campaign in our shared mission to support women living with HIV in advocating for our health and rights," said Naina Khanna, Executive Director of PWN-USA. "Women living with HIV have unique needs and face specific challenges that healthcare providers should take into account when considering treatment and care plans." The full research reports on Merck are available to download free of charge at:
http://www.analystsreview.com/Jul-23-2014/MRK/report.pdf
--
AstraZeneca plcResearch Reports
On July 18, 2014, AstraZeneca plc (AstraZeneca) announced the proposed designs for its new Global R&D Centre and Corporate Headquarters in Cambridge in the UK. The Company reported that the new facility will be located on the Cambridge Biomedical Campus (CBC), and the facility plans include designs for the Global Centre, an R&D Enabling Building, and an Energy Centre. Further, the facility is expected to bring together AstraZeneca's small molecule and biologics research and development activity. The site is expected to go online in late 2016, with construction expected to begin in early 2015. The full research reports on AstraZeneca are available to download free of charge at:
http://www.analystsreview.com/Jul-23-2014/AZN/report.pdf
--
Novartis AG Research Reports
On July 17, 2014, Novartis AG (Novartis) reported Q2 2014 financial results. In Q2 2014, the Company's net sales were $14.6 billion, up 2.0% YoY. The Company noted that year-on-year comparisons are based on 2013 data excluding the divested blood transfusion diagnostics unit. Q2 2014 net income was $2.6 billion, or $1.05 per share, compared with $2.5 billion, or $1.01 per share, in Q2 2013. "Novartis delivered solid financial performance with core margin expansion in the second quarter and first half. Pharmaceuticals, in particular, showed improved productivity, driving core operating leverage for the Group," said Joseph Jimenez, CEO of Novartis. The full research reports on Novartis are available to download free of charge at:
http://www.analystsreview.com/Jul-23-2014/NVS/report.pdf
--
Teva Pharmaceutical Industries Ltd. Research Reports
On July 18, 2014, Teva Pharmaceutical Industries Ltd. (Teva) announced that it intends to release its Q2 2014 financial results on July 31, 2014, at 7:00 a.m. ET. On the same day, the Company has scheduled a conference call and live webcast, at 8:00 a.m. ET, to discuss Teva's results as well as overall business environment. The full research reports on Teva are available to download free of charge at:
http://www.analystsreview.com/Jul-23-2014/TEVA/report.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
